KEY POINTS:
SYDNEY - Neuren Pharmaceuticals has successfully completed a safety and tolerability trial of its traumatic brain injury drug NNZ-2566.
Chief executive David Clarke said the trial on healthy volunteers was conformation that NNZ-2566 was safe.
Planning was now underway to test the drug on patients with traumatic brain injuries, which has a target market of US$1.5 billion ($2.18 billion) in the United States alone, Mr Clarke said.
Neuren is also exploring other opportunities for the drug such as vascular dementia and stroke-related injuries.
- AAP
